Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KamadaKMDA +1.73%83 Net Margin % is 9.13% as of Mar. 2026, which is 16% above its 10-year median of 7.85. GuruFocus rates KMDA with a GF Score™ of 83/100 and a GF Value™ of $8.01 (Modestly Undervalued). Among 961 Drug Manufacturers companies, Kamada ranks better than 67.53% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Kamada's Net Income for the
three
months ended in Mar. 2026 was $4.1 Mil. Kamada's Revenue for the
three
months ended in Mar. 2026 was $45.2 Mil. Therefore, Kamada's net margin for the quarter that ended in Mar. 2026 was 9.13%.
The historical rank and industry rank for Kamada's Net Margin % or its related term are showing as below:
KMDA'
s Net Margin % Range Over the Past 10 Years
Min: -8.69 Med: 7.85 Max: 19.48
Current: 11.21
KMDA's Net Margin % is ranked better than 67.53% of 961
companies
in the Drug Manufacturers industry
Industry Median: 5.54
vs KMDA: 11.21
Kamada (NAS:KMDA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Kamada Net Margin % Related Terms
Kamada Net Margin % Historical Data
* Premium members only.
The historical data trend for Kamada's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kamada Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kamada's Net Margin % distribution charts can be found below:
* The bar in red indicates where Kamada's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kamada (KMDA) has a Net Margin % of 9.13% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Kamada and its competitors. This is 16% above median its historical median of 7.85. According to the industry distribution chart, Kamada ranks #312 out of 961 companies in the Drug Manufacturers industry, placing it in the top 32.5%.
Is Kamada's Net Margin % too high?
Kamada's current Net Margin % of 9.13% is 16% above median its 10-year median of 7.85. The Drug Manufacturers industry median Net Margin % is 5.54. Kamada's value of 9.13% is 64.8% above this industry median. Based on the distribution chart, Kamada ranks #312 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Kamada has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kamada's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kamada ranks #312 out of 961 companies for Net Margin %. This puts Kamada in the upper half of its industry. The industry median Net Margin % is 5.54. Kamada's value of 9.13% is 64.8% above this benchmark. While the company's 10-year median is 7.85 vs. the industry median of 5.54, Kamada has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.54, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kamada's current Net Margin % of 9.13% is 64.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Kamada and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kamada's current Net Margin % is 9.13%, which is 16% above median its own 10-year median of 7.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kamada stock overvalued right now?
Based on GuruFocus' analysis, Kamada (KMDA) is currently considered Modestly Undervalued. The stock's GF Value™ is $8.01, compared to a current price of $7.06 — trading 11.9% below its estimated fair value. The current Net Margin % is 9.13%, which is 16% above median its 10-year median of 7.85 and 64.8% above the Drug Manufacturers industry median of 5.54. Kamada's overall GF Score™ is 83/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Kamada (KMDA), the current Net Margin % is 9.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kamada (KMDA) Overvalued in 2026?
Based on GuruFocus' analysis, Kamada stock appears to be undervalued.
The current stock price of $7.06 is trading 11.9% below its estimated GF Value™ of $8.01.
GuruFocus considers Kamada to be Modestly Undervalued.
Key valuation signals for KMDA:
Net Margin %: 9.13% (16% above median its 10-year median of 7.85)
GF Value™: $8.01 vs. price of $7.06 (11.9% below fair value)
Industry Position: 64.8% above the Drug Manufacturers median (#312 of 961)
No single metric tells the full story. See the KMDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
83GF Score
Get the complete analysis for KMDA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMDA has been successfully added to your 
